Immuron (IMRN) Non Operating Interest Expenses (2016 - 2024)

Immuron (IMRN) posted quarterly Non Operating Interest Expenses of -$2629.6 for Q4 2024, up 98.68% quarter-over-quarter from -$198652.0 in Q4 2018.

Immuron (IMRN) Non Operating Interest Expenses (2016 - 2024) Analysis & Trends

Immuron's Non Operating Interest Expenses history runs 4 years deep, the most recent figure standing at -$2629.6 for Q4 2024.

In Q4 2024, Non Operating Interest Expenses changed N/A year-over-year to -$2629.6; the TTM figure through Dec 2024 stood at -$214157.0 (changed N/A YoY), while the FY2022 annual figure was -$4441.2, changed N/A from the prior year.
Non Operating Interest Expenses for Q4 2024 stood at -$2629.6, up from -$198652.0 in the prior quarter.
The five-year high for Non Operating Interest Expenses was -$2629.6 in Q4 2024, with the low at -$2629.6 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non Operating Interest Expenses (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	11.00 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	39.74 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	82.05 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-4.89 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	20.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	93.62 Mn
10	Immuron	6.75 Mn	6.73 Mn	-	-

Download Data